Researchers from TUM studying the T cell response to chronic infection have discovered a late dominance of low-affinity TCR clones.
Concerns that use of ACE inhibitors and ARBs could increase susceptibility to COVID-19 are not fully supported by current research.
A physician, Dr. Giovanni Monteleone MD PhD, outlines the implications of COVID-19 for Ulcerative Colitis and Crohn’s Disease patients.
Everything that you should know about Inovio (NASDAQ: INO) receiving $5 million from Bill and Melinda Gates for its COVID-19 vaccine program.
Clinical Trial Demonstrates Enhancement of Immune Response to HIV by Gilead’s TLR7 Agonist Vesatolimod
Gilead (Nasdaq: GILD) has announced clinical trial results demonstrating the enhancement of the immune response to HIV by the TLR7 agonist Vesatolimod.
Moderna, Inc. (Nasdaq: MRNA) has announced the completion of enrollment for a Phase 2 study evaluating its cytomegalovirus vaccine.
Timeline and latest updates regarding phase 3 trials of the antiviral agent remdesivir for the treatment of COVID-19 initiated by Gilead.
OPKO Health (NASDAQ: OPK) company BioReference Laboratories, Inc. is offering a coronavirus antibody test: latest updates and timeline.